Morgan Stanley raised the firm’s price target on Biogen to $351 from $345 and keeps an Overweight rating on the shares after Q4 revenues beat by about 4% and EPS beat by about 16%. 2023 guidance for revenues to be down by a mid-single digit percentage was generally in-line with consensus, added the firm, which says Alzheimer’s updates are the keys to driving the shares higher in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
- Biogen reports Q4 EPS $4.05, consensus $3.48
- Notable companies reporting before tomorrow’s open
- Hyperfine could have ‘interesting’ opportunity in Alzheimer’s, says Evercore ISI
- Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
